Literature DB >> 18237139

Entropy drives integrin alphaIIbbeta3:echistatin binding--evidence from surface plasmon resonance spectroscopy.

Roy R Hantgan1, Mary C Stahle, David A Horita.   

Abstract

This investigation examined the molecular mechanisms that enable the alphaIIbbeta3 integrin to bind efficiently, tightly, and selectively to echistatin, an RGD disintegrin. We used surface plasmon resonance spectroscopy to measure the rate, extent, and stability of complexes formed between micellar alphaIIbbeta3 and recombinant echistatin (rEch) mutants, immobilized on the surface of a biosensor chip. alphaIIbbeta3 bound readily and tightly to wild-type RGD-rEch and RGDF-rEch but not to RGA-rEch or AGD-rEch, demonstrating that both of those charged moieties contribute to integrin recognition. van't Hoff analysis of the temperature dependence of the RGD-rEch K d data yielded an unfavorable enthalpy change, Delta H degrees = 14 +/- 3 kcal/mol, offset by a favorable entropy term, TDelta S degrees = 23 +/- 3 kcal/mol. Eyring analysis of the temperature dependence of the kinetic parameters yielded Delta H a degrees (++) = 9 +/- 2 kcal/mol and TDelta S a degrees (++) = -4 +/- 2 kcal/mol, indicating that a substantial activation enthalpy barrier and a smaller activation entropy hinder assembly of the encounter complex. Thus, equilibrium thermodynamic data demonstrate that entropy is the dominant factor stabilizing integrin:echistatin binding, while transition-state thermodynamic parameters indicate that the rate of complex formation is enthalpy-limited. When electrostatic contacts are the major source of receptor:ligand stability, theory and experiment indicate that entropy-favorable ion-pair desolvation often provides the driving force for molecular recognition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237139     DOI: 10.1021/bi701877a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis.

Authors:  John T Melchior; Janet K Sawyer; Kathryn L Kelley; Ramesh Shah; Martha D Wilson; Roy R Hantgan; Lawrence L Rudel
Journal:  J Lipid Res       Date:  2013-06-26       Impact factor: 5.922

2.  Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.

Authors:  Lawrence C Blume; Theresa Patten; Khalil Eldeeb; Sandra Leone-Kabler; Alexander A Ilyasov; Bradley M Keegan; Jeremy E O'Neal; Caroline E Bass; Roy R Hantgan; W Todd Lowther; Dana E Selley; A Llyn C Howlett
Journal:  Mol Pharmacol       Date:  2016-11-28       Impact factor: 4.436

3.  Dynamic regulation of fibrinogen: integrin αIIbβ3 binding.

Authors:  Roy R Hantgan; Mary C Stahle; Susan T Lord
Journal:  Biochemistry       Date:  2010-11-02       Impact factor: 3.162

4.  PROBING αIIbβ3: LIGAND INTERACTIONS BY DYNAMIC FORCE SPECTROSCOPY AND SURFACE PLASMON RESONANCE.

Authors:  Roy R Hantgan; Martin Guthold; Samrat Dutta; David A Horita
Journal:  Nano Life       Date:  2013

5.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

6.  Slow dissociation of a charged ligand: analysis of the primary quinone Q(A) site of photosynthetic bacterial reaction centers.

Authors:  Jennifer Madeo; Maja Mihajlovic; Themis Lazaridis; M R Gunner
Journal:  J Am Chem Soc       Date:  2011-10-11       Impact factor: 15.419

7.  Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Authors:  Darpan N Pandya; Roy Hantgan; Mikalai M Budzevich; Nancy D Kock; David L Morse; Izadora Batista; Akiva Mintz; King C Li; Thaddeus J Wadas
Journal:  Theranostics       Date:  2016-03-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.